Pharmacy benefit managers are combating President Donald Trump’s administration’s efforts to end drug rebates, according to a Washington Examiner report.
The Pharmaceutical Care Management Association (PCMA) said in a report released Wednesday that drugmakers are to blame for the nation’s rising drug costs, not PBMs. The Trump administration has claimed PBMs are a significant driver of high prices.
According to the Examiner report, the administration says the current rebate system incentivizes high list prices since the PBM earns a percentage of that rebate.
PCMA, however, says list prices are on the rise regardless of whether the PBMs receive rebates.